Bexarotene

Basic Information

Item Value
DrugBank ID DB00307
Evidence Level L5 (Computational Prediction)
Number of Predicted Indications 37

Predicted Indications (TxGNN)

The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.

# Indication Source
1 primary cutaneous B-cell lymphoma KG + DL
2 Sezary syndrome KG + DL
3 lymphosarcoma KG + DL
4 lymph node cancer KG + DL
5 granulomatous slack skin disease KG + DL
6 primary organ-specific lymphoma KG + DL
7 folliculotropic mycosis fungoides KG + DL
8 localized pagetoid reticulosis KG + DL
9 myelodysplastic syndrome KG + DL
10 acute lymphoblastic leukemia (disease) KG + DL
11 refractory cytopenia of childhood KG + DL
12 unclassified myelodysplastic syndrome KG + DL
13 acute lymphoblastic/lymphocytic leukemia KG + DL
14 partial deletion of the long arm of chromosome 5 KG + DL
15 T-cell prolymphocytic leukemia KG + DL
16 lymphoma KG + DL
17 Crohn’s colitis KG + DL
18 lipoid nephrosis KG + DL
19 aregenerative anemia KG + DL
20 severe congenital hypochromic anemia with ringed sideroblasts KG + DL
21 lymphoma, non-Hodgkin, familial KG + DL
22 interdigitating dendritic cell sarcoma KG + DL
23 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma KG + DL
24 chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation KG + DL
25 psoriasis KG + DL
26 indolent primary cutaneous T-cell lymphoma KG + DL
27 reticulum cell sarcoma KG + DL
28 parapsoriasis KG + DL
29 obsolete Hodgkin’s granuloma KG + DL
30 mycosis fungoides and variants KG + DL
31 subcutaneous panniculitis-like T-cell lymphoma KG + DL
32 B-cell neoplasm KG + DL
33 immunodeficiency, common variable KG + DL
34 colon adenocarcinoma KG + DL
35 pityriasis lichenoides KG + DL
36 persistent polyclonal B-cell lymphocytosis KG + DL
37 acute lichenoid pityriasis KG + DL

Disclaimer

These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.


← Back to Drug Search


Copyright © 2026 藥提醒科技有限公司 (yao.care). 本報告僅供研究參考,不構成醫療建議。

This site uses Just the Docs, a documentation theme for Jekyll.